Dan Yarosh
MENDING LIFE
WHY AND HOW CELLS PROTECT THEIR DNA
Essays on Genome Stability, Disease, Aging and Therapy
3. Turning Down the Alarm: How IL-10 Suppresses DNA Repair and Immunity
The immune system is often described as a defense force—detecting threats, attacking invaders, and eliminating damaged cells. But equally necessary is its ability to stand down.
Inflammation is essential for survival, and it is a powerful weapon against pathogens and damaged cells. But there is collateral damage in inflamed tissue, including oxidative stress, DNA damage from that oxidation, tissue fibrosis during recovery, and stem cell depletion. To limit the side effects, immune responses are tightly regulated by inhibitory cytokines, regulatory cells, and metabolic checkpoints. Additional molecular signals mark the end of the response, and a return to normality.
One of the most important of these signals is the cytokine IL-10. IL-10 is best known as a “peacekeeping” molecule that suppresses inflammation and promotes tissue healing. But its expression in the wrong place or at the wrong time can dampen DNA repair, give safe harbor for damaged cells to survive, and allow cancer cells to grow out. Understanding how IL-10 interacts with genome maintenance reveals a hidden connection between immune tolerance and DNA repair.
The Big Picture: Balancing Protection and Restraint
IL-10 sits at the center of this immune regulatory network. Produced by macrophages, T cells, B cells, and epithelial cells, IL-10 limits immune activation by suppressing pro-inflammatory signaling. IL-10 signals through a dedicated receptor complex that activates the transcription factor STAT3. This pathway induces broad anti-inflammatory and cytoprotective programs. It promotes resolution and repair. It calls back the attack and normalizes tissue. But in doing so, it also reshapes how cells handle genomic stress.
How IL-10 Reprograms Cellular Stress Responses
IL-10 delayed release after DNA Damage
Solar UV causes a sunburn to appear in human skin after about 24 hours. By 72 hours, IL-10 levels peak and inflammation begins to resolve. The rise in IL-10 is caused by UV-induced DNA damage (cyclobutane pyrimidine dimers) and enhancing DNA repair of these lesions reduces IL-10 release. IL-10 switches the immune response to a suppression mode. Unfortunately, nascent skin cancer cells lurking in the tissue (which might be eliminated by immune cells) now have free reign to divide into full blown skin cancers. It’s tricky to know when to call off the hounds if a few bad actors might remain in the bush.
Suppression of DNA Damage Signaling
IL-10 reduces the activity of major inflammatory transcription factors, including NF-κB and AP-1. By lowering inflammatory oxidative stress, IL-10 reduces immediate DNA injury. But it also tunes down recruitment of DNA repair enzymes. Cells become less responsive to genotoxic signals and tissue shows weaker surveillance that detects residual damage.
IL-10 promotes cell survival and limits apoptosis. It enhances expression of anti-apoptotic proteins and suppresses pro-death pathways activated by DNA damage. This favors cell preservation over elimination. While beneficial during the end phase of wound healing, this becomes dangerous when damaged cells persist.
IL-10 must perform a balancing act to have just enough damage response but not too much.
Immune Suppression and Genome Stability: A Delicate Trade-Off
Under normal conditions, IL-10 arrives to help tissues recover from stress. But when IL-10 signaling is chronically elevated, cells enter a permissive state in which genomic integrity is put at risk. This shift has three major consequences:
1. Reduced Checkpoint Enforcement. DNA damage checkpoints slow cell division to allow repair. IL-10 weakens these brakes by dampening stress signaling. Cells may continue cycling despite incomplete repair.
2. Tolerance of Damaged Cells. IL-10 allows genetically abnormal cells to persist because it dampens immune surveillance. Immune cells that would normally eliminate unstable cells become less active and damaged cells grow out.
3. Promotion of Mutational Accumulation. Over time, imperfect repair and continued proliferation lead to mutation buildup, chromosomal rearrangements, and clonal expansion. These variously mutated cells are the feedstock of cancer.
When It Goes Wrong: Cancer, Infection, and Chronic Disease
The effects of IL-10 on DNA repair are most evident in disease settings.
Skin Cancer
Skin cancers are highly immunogenic and are easily rejected by a fully functional immune system. General immunosuppression, such as in organ transplant patients, greatly increases skin cancer rates. Solar UV also instigates skin cancer, because the DNA damage it causes not only induces mutations but also floods skin with IL-10 and suppresses the immune system. Our native DNA repair is a key defense against these effects.
Other Cancers
Many tumors actively produce IL-10 or induce IL-10 secretion by surrounding immune cells. This creates a microenvironment that inhibits anti-tumor immunity, reduces DNA damage checkpoints and promotes therapy resistance. Cancer cells exploit IL-10 to survive the body’s defenses.
Chronic Infection
Persistent viral and bacterial infections often elevate IL-10 levels. While this limits tissue damage, it also allows infected cells with damaged DNA to persist. This contributes to cancer risk in chronic hepatitis, Helicobacter infection, and other inflammatory diseases.
IL-10 in Therapy: Friend and Foe
Because of its immunosuppressive effects, IL-10 has been explored as a therapeutic agent. In autoimmune and inflammatory diseases, particularly neuroimmune diseases, IL-10 can reduce tissue damage and promote healing. It’s still in the clinical testing phase, and while early studies showed promise, later clinical trials have shown mixed results, highlighting that IL-10 has complex, sometimes contrary effects.
DNA repair enzymes are included in several commercial sunscreen and anti-aging topical products to enhance the speed and completeness of DNA repair (these will be covered in a later post). These enzymes reduce IL-10 expression and increase the regression of pre-skin cancers (actinic keratosis), presumably by letting the natural immune system take over and hunt them down.
Key Takeaways
- IL-10 is a central suppressor of inflammation and immune activation
- It is induced by DNA damage
- It reduces DNA damage signaling and checkpoint enforcement
- Chronic IL-10 promotes tolerance of genetically unstable cells
- Tumors exploit IL-10 to evade immune and repair mechanisms
- Immune suppression and genome maintenance are tightly linked
The next essay will describe how a DNA repair system is used to fight viruses, especially DNA in places it’s not supposed to be. It’s another connection between DNA repair an immunity.
If you enjoyed the essay, please recommend it to a friend and post the link on your favorite site. Thank You!
References & Further Reading
1. Moore, K. W., et al. (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 19, 683–765.
Classic review of IL-10 biology.
2. Saraiva, M., & O’Garra, A. (2010). The regulation of IL-10 production by immune cells. Nat Rev Immunol, 10, 170–181.
Mechanisms of IL-10 regulation.
3. Murray, P. J. (2007). The JAK-STAT signaling pathway: Input and output integration. J Immunol, 178, 2623–2629.
STAT3 signaling downstream of IL-10.
4. Nishigori C., et al. (1996). Evidence that DNA damage triggers interleukin 10 cytokine production in UV-irradiated murine keratinocytes. Proc Natl Acad Sci U S A, 93, 10354-103599.
UV induced DNA damage initiates IL-10 release
5. Ruffell, B., & Coussens, L. M. (2015). Macrophages and therapeutic resistance in cancer. Cancer Cell, 27, 462-472.
Immune suppression and tumor evolution.
6. Landskron, G., et al. (2014). Chronic inflammation and cytokines in cancer development. J Immunol Res 2014, 149185.
Cytokines and genomic instability.
7. Schreiber, R. D., et al. (2011). Cancer immunoediting: Integrating immunity’s roles. Science, 331, 1565–1570.
Immune selection and mutation.
8. Mittal, D., et al. (2014). New insights into cancer immunoediting. Curr Opin Immunol, 27, 16–25.
Immune tolerance and tumor diversity.
9. O’Garra, A., & Vieira, P. (2007). TH1 cells control themselves by producing IL-10. Nat Rev Immunol, 7, 425–428.
Self-regulation of immunity.